An observational study in Acute Intermittent Porphyria (AIP), sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Icahn School of Medicine at Mount Sinai · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is the only one that started in 2022, is one of 6 observational ones, and was the 12th registered.
21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.
Browse Porphyria, Acute Intermittent studies →2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:
The American Porphyrias Expert Collaborative · Sites in United States
Ages 1 min+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2
First in 2003; this study’s year is marked. 1 started in 2022.
Median enrollment 28 across the 6 interventional studies, 149 across the 6 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 7 most frequent:
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
Icahn School of Medicine at Mount Sinai has 1 study filed under Porphyria, Acute Intermittent — fewer than ten, so there is no comparison to draw.
1 of the studies in Porphyria, Acute Intermittent with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02935400The University of Texas Medical Branch, GalvestonAcute Porphyria Biomarkers for Disease Activity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study proposes to identify the predisposing/protective modifying genes that underlie the acute attacks in symptomatic patients with Acute Intermittent Porphyria (AIP), an autosomal dominant inborn error of heme biosynthesis.
A member of an AIP family who possesses an AIP pathogenic mutation and is/has been symptomatic (experienced acute attacks). Parents with no known HMBS mutations or heterozygote with familial mutation or a first, second or third degree relative of the above.
Inclusion Criteria:
A member of an AIP family, defined as (must meet one of the following):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Symptomatic patients with Acute Intermittent Porphyria (AIP) A member of an AIP family who possesses an AIP pathogenic mutation and is/has been symptomatic (experienced acute attacks). Parents with no known HMBS mutations or heterozygote with familial mutation or a first, second or third degree relative of the above.
Odds ratios (OR) of the effects of identified modifier genes/variants
There are no primary and secondary endpoints. This is an exploratory genetic study. Exploratory Endpoints: Odds ratios (OR) of the effects of identified modifier genes/variants. (If putative predisposing or protective gene variants are identified)
Time frame: Day 1
Plan to share: No — Not feasible.
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Jun 2029, 81 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Porphyria, Acute Intermittent →
Icahn School of Medicine at Mount Sinai →